Search details
1.
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Nature
; 629(8013): 919-926, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38589574
2.
Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Nat Chem Biol
; 17(10): 1065-1074, 2021 10.
Article
in English
| MEDLINE | ID: mdl-34168367
3.
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Nat Chem Biol
; 17(8): 925, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-34188221
4.
Author Correction: Selective inhibitors of mTORC1 activate 4EBP1 and suppress tumor growth.
Nat Chem Biol
; 17(11): 1209, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34616097
5.
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Cancer Discov
; : OF1-OF24, 2024 Apr 09.
Article
in English
| MEDLINE | ID: mdl-38593348
6.
Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors.
J Med Chem
; 66(1): 149-169, 2023 01 12.
Article
in English
| MEDLINE | ID: mdl-36533617
7.
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS.
Science
; 381(6659): 794-799, 2023 08 18.
Article
in English
| MEDLINE | ID: mdl-37590355
8.
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers.
Nat Cell Biol
; 20(9): 1064-1073, 2018 09.
Article
in English
| MEDLINE | ID: mdl-30104724
Results
1 -
8
de 8
1
Next >
>>